Business Wire

CCIX Consortium and Green Computing Consortium Announce Collaboration

Share

The CCIX Consortium (CCIX) and Green Computing Consortium (GCC) announced today that they have signed a Memorandum of Understanding (MoU) to collaborate on endorsing CCIX as a unified industry standard interconnect technology and an essential requirement in the GCC server standards reference guide. Through this partnership, GCC and CCIX will jointly promote the awareness and the adoption of CCIX technology in the server ecosystem.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190409005046/en/

With the execution of this MoU, CCIX and GCC have agreed to complement the GCC green computing standards framework with CCIX as one of the pillar technologies to further the ecosystem of green computing. The long-term goals of this collaboration are centered on advancing high-performance, low-power green computing with heterogeneous cache coherent acceleration architectures.

The CCIX Consortium was founded to develop and promote the adoption of an industry standard specification to enable coherent interconnect technologies between general-purpose processors and acceleration devices for efficient heterogeneous computing. Heterogeneous compute architectures leverage accelerators to complete today’s compute tasks faster and with lower power consumption than the processor working on its own. CCIX’s non-proprietary standard enables vendors of processors, accelerators and other peripheral devices to simplify how heterogeneous systems are architected, establishing a seamless chip-to-chip communication and take advantage of the additional bandwidth, reduced latency and lower power consumption opportunities that CCIX provides.

“The CCIX Consortium is honored to collaborate with the Green Computing Consortium in the promotion of the CCIX Standard among the GCC membership,” said Gaurav Singh, Chairman, CCIX Consortium. “This collaboration is further validation of our leadership in coherent interconnect technologies and will enable servers based on the GCC specifications to provide outstanding performance.”

The Green Computing Consortium is dedicated to the ecosystem development and market promotion of green computing products based on the Arm computing chipsets technology. GCC works on the standardization, test and certification, system enablement, pilot programs, open source projects, and education and training of young professionals. As a state-of-the-art architecture and standards overview, GCC released in 2018 the“Green Computing Consortium Server Technical Standards Report.”

“GCC believes that the CCIX specification provides key technology for heterogeneous acceleration that enables the consortium members to deliver green computing servers with unprecedented power efficiency and price/performance that meets the next generation cloud and datacenter requirements,” said Hong Mei, General Director, GCC. “We believe the CCIX Consortium is a leader in providing coherent interconnect technologies and greatly value this strategic partnership.”

About CCIX Consortium, Inc.

CCIX Consortium was founded to enable a new class of interconnect focused on emerging acceleration applications such as machine learning, network processing, storage off-load, in-memory database and 4G/5G wireless technology. The standard allows processors based on different instruction set architectures to extend the benefits of cache coherent, peer processing to acceleration devices including FPGAs, GPUs, network/storage adapters, intelligent networks, and custom ASICs, allowing system designers to seamlessly integrate the right combination of heterogeneous components for their specific system needs. For more information, please visit www.ccixconsortium.com.

About Green Computing Consortium

Green Computing Consortium is organized, on a voluntary, equitable, mutually beneficial and cooperative basis, by all interested parties of the industry, including but not limited to technology provider, manufacturer, system integrators and business users. The mission of the Consortium is following the technology trends of open source software and open hardware, gathering strength of all interested parties in the industry chain, and providing end business users with easier use and management green energy-saving products based on the Arm computing chipsets technology. For more information, please visit www.opengcc.org.

Contact information

CCIX Consortium:
Matthew Baxter, Nereus
mbaxter@nereus-worldwide.com
+1.503.619.2676

Green Computing Consortium:
Mr. Li Weizhong
liwz@itssmedia.cn

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FDA Approves OTEZLA® (apremilast) for the Treatment of Oral Ulcers Associated with Behçet’s Disease19.7.2019 17:59:00 CESTPress release

Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has approved OTEZLA® (apremilast) 30 mg twice daily (BID) for the treatment of adult patients with oral ulcers associated with Behçet’s Disease. OTEZLA, an oral, selective inhibitor of phosphodiesterase 4 (PDE4), is the first and only approved treatment option for oral ulcers associated with Behçet’s Disease, a rare, chronic, multisystem inflammatory disease that is difficult to treat. “Oral ulcers are a recurring and debilitating manifestation that affects nearly everyone living with Behçet’s Disease, and have an important negative impact on the quality of life for these patients,” said Yusuf Yazici, M.D., Clinical Associate Professor, Department of Medicine, New York University Langone Health. “In the clinical trial, OTEZLA demonstrated improvements in measures of oral ulcers at week 12. OTEZLA has the potential to be a needed treatment option for U.S. patients and their physicians, who

Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer19.7.2019 13:05:00 CESTPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2 The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1 “The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which ar

Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis19.7.2019 12:30:00 CESTPress release

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development. Gilead’s antiviral portfolio include

Schlumberger Announces Second-Quarter 2019 Results19.7.2019 11:00:00 CESTPress release

Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2019 Mar. 31, 2019 Jun. 30, 2018 Sequential Year-on-year Revenue $8,269 $7,879 $8,303 5% 0% Pretax segment operating income $968 $908 $1,094 7% -12% Pretax segment operating margin 11.7% 11.5% 13.2% 17 bps -148 bps Net income - GAAP basis $492 $421 $430 17% 14% Net income, excluding charges & credits* $492 $421 $594 17% -17% Diluted EPS - GAAP basis $0.35 $0.30 $0.31 17% 13% Diluted EPS, excluding charges & credits* $0.35 $0.30 $0.43 17% -19% North America revenue $2,801 $2,738 $3,139 2% -11% International revenue $5,463 $5,037 $5,065 8% 8% North America revenue, excluding Cameron $2,243 $2,178 $2,546 3% -12% International revenue, excluding Cameron $4,761 $4,469 $4,387 7% 9% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commente

Schlumberger Appoints Olivier Le Peuch as CEO19.7.2019 10:46:00 CESTPress release

Schlumberger Limited (NYSE: SLB) announced today that its Board of Directors has appointed Olivier Le Peuch as its Chief Executive Officer and member of the Schlumberger Board, effective August 1, 2019. Mr. Le Peuch succeeds Paal Kibsgaard, who will retire as Chief Executive Officer effective that same date. Also effective August 1, Mr. Kibsgaard will step down as Chairman of the Board and retire as a member of the Board of Directors. Mr. Kibsgaard will retire after more than 22 years of service to the Company, including eight years as CEO and four years as Chairman. Effective the same date, Mark G. Papa, a current non-independent director, will become non-executive Chairman of the Board. Peter Currie will continue to serve as the Board’s Lead Independent Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190719005161/en/ Olivier Le Peuch is appointed Chief Executive Officer and a member of the Schlumberger Board, effe

Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK19.7.2019 10:00:00 CESTPress release

Fluke Corp., the global leader in test and measurement instruments, has acquired Ismaning, Germany-based PRÜFTECHNIK, a market leader in precision laser shaft alignment, condition monitoring, and non-destructive testing. “Fluke’s acquisition of PRÜFTECHNIK reflects the growing importance our customers place on reliability systems to keep their equipment in optimum operating condition,” said Marc Tremblay, president of Fluke Corporation. “This business will help us usher in the next generation of solutions for our industrial customers.” Fluke Corporation For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail fluke-info@fluke.com or visit the Fluke Web site at http://www.fluke.com. About Fluke Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measu